PRO-CIPROFLOXACIN INTRAVENOUS INFUSION BP DIN 02571935
Health Canada record
| Active ingredient(s) | CIPROFLOXACIN 2 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01MA02 CIPROFLOXACIN |
| Original market date | |
| Current status date | 25-Sep-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pro Doc Limitée — licence 100182, currently licensed, last inspection rating C (2025-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CIPROFLOXACIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02237514 | CIPRO ORAL SUSPENSION | BAYER INC | Suspension | CIPROFLOXACIN 500 MG | Marketed |
| 02304759 | CIPROFLOXACIN INTRAVENOUS INFUSION BP | SANDOZ CANADA INCORPORATED | Solution | CIPROFLOXACIN 2 MG | Marketed |
| 02237334 | CIPRO I.V. MINIBAGS 2MG/ML | BAYER INC | Solution | CIPROFLOXACIN 2 MG | Cancelled Post Market |
| 02312123 | CIPROFLOXACIN INJECTION | FRESENIUS KABI CANADA LTD | Solution | CIPROFLOXACIN 2 MG | Cancelled Pre Market |
| 02301903 | CIPROFLOXACIN INJECTION USP | PFIZER CANADA ULC | Solution | CIPROFLOXACIN 2 MG | Cancelled Post Market |
| 02256789 | CIPROFLOXACIN INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | CIPROFLOXACIN 10 MG | Cancelled Post Market |
| 02289946 | CIPROFLOXACIN INJECTION, USP | BAXTER CORPORATION | Solution | CIPROFLOXACIN 2 MG | Cancelled Post Market |
| 02267462 | CIPROFLOXACIN INTRAVENOUS INFUSION | TEVA CANADA LIMITED | Solution | CIPROFLOXACIN 2 MG | Cancelled Post Market |
| 02304546 | CIPROFLOXACIN INTRAVENOUS INFUSION, BP | APOTEX INC | Solution | CIPROFLOXACIN 2 MG | Dormant |
| 02311895 | CIPROFLOXACIN OMEGA | OMEGA LABORATORIES LIMITED | Solution | CIPROFLOXACIN 2 MG | Cancelled Pre Market |
| 02249650 | NU-CIPROFLOXACIN TABLETS | NU-PHARM INC | Tablet | CIPROFLOXACIN 750 MG | Cancelled (Unreturned Annual) |
| 02249626 | NU-CIPROFLOXACIN TABLETS | NU-PHARM INC | Tablet | CIPROFLOXACIN 100 MG | Cancelled (Unreturned Annual) |
| 02249642 | NU-CIPROFLOXACIN TABLETS | NU-PHARM INC | Tablet | CIPROFLOXACIN 500 MG | Cancelled (Unreturned Annual) |
| 02249634 | NU-CIPROFLOXACIN TABLETS | NU-PHARM INC | Tablet | CIPROFLOXACIN 250 MG | Cancelled (Unreturned Annual) |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38348 | 2026-09-25 | Supplement to an Abbreviated New Drug Submission (SANDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for CIPROFLOXACIN
6 valid EDQM Certificates of Suitability from 6 holders. 20 active FDA Drug Master Files.
Request a quote for PRO-CIPROFLOXACIN INTRAVENOUS INFUSION BP